Dexcom Inc

NASDAQ:DXCMUnited States

Yesterday

Show headlines and story abstract

• DJ Did Your Heart Skip a Beat? Your Wearable Knows. -2-, from 17 hours ago by Dow Jones

  17 hours ago by Dow Jones
  Companies Mentioned: DXCM, SSNHZ, AAPL, IRTC, ABT
  
  The clinical-grade sensor firms have plenty of growth opportunities in their medical markets, according to William Blair analyst Margaret Kaczor Andrew, who has Buy ratings on iRhythm, DexCom, and Abbott. About 15 million Americans a year come to their doctor with palpitations. Another 12 million may suffer from symptomless AFib. Both DexCom and Abbott recently got FDA approval to market continuous glucose-monitoring devices to the 25 million people with Type 2 diabetes who don't need insulin. Some 100 million Americans are considered prediabetic.
  

• DJ Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com, from 19 hours ago by Dow Jones

  19 hours ago by Dow Jones
  Companies Mentioned: DXCM, SSNHZ, AAPL, IRTC, ABT
  The clinical-grade sensor firms have plenty of growth opportunities in their medical markets, according to William Blair analyst Margaret Kaczor Andrew, who has Buy ratings on iRhythm, DexCom, and Abbott. About 15 million Americans a year come to their doctor with palpitations. Another 12 million may suffer from symptomless AFib. Both DexCom and Abbott recently got FDA approval to market continuous glucose-monitoring devices to the 25 million people with Type 2 diabetes who don't need insulin. Some 100 million Americans are considered prediabetic. If Big Tech has eased back its investment in clinical trials of their smart wearables, drug and device companies are carrying on. Johnson & Johnson recruited 26,000 people over the age of 65 to see if early detection of irregular heart rhythms by the Apple Watch can reduce bad outcomes such as stroke; J&J specializes in heart arrhythmia treatments. ura supplies smart rings to a bunch of preventive health studies. IRhythm is supporting randomized trials with tens of thousands of subjects in the U.S. and Europe to test whether screening for AFib with the Zio patch can reduce the risk of stroke or heart failure. Earlier studies weren't decisive enough to convince the U.S. Preventive Services Task Force to add Zio to screening guidelines. The clinical sensor firms are advancing cautiously into screening and prevention. They saw how the stock of the blood-oxygen sensing firm Masimo was cut in half after the firm spent $1 billion in 2022 on a consumer product business. Facing an activist investor campaign, Masimo recently announced it would unload the consumer business. "We have to move down the acuity curve," says DexCom CEO Sayer. "But I don't think we can just jump to the end of it." Write to Bill Alpert at william.alpert@barrons.com This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. Corrections & Amplifications IRhythm says it will sell two million ECG patches this year. A previous version of this article and graphic said the company would sell three million. (END) Dow Jones Newswires June 28, 2024 19:28 ET (23:28 GMT)